Danusertib (formerly PHA-739358) - A novel combined Pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor

Recent Results in Cancer Research

Volumn 184, Issue , 2010, Pages 199-214

  Brümmendorf, Tim H ^a   Gontarewicz, Artur ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 2 [[3 [4 [5 [2 (3 FLUOROANILINO) 2 OXOETHYL] 1H PYRAZOL 3 YLAMINO] 7 QUINAZOLINYLOXY]PROPYL](ETHYL)AMINO]ETHYL DIHYDROGEN PHOSPHATE; 4 [[9 CHLORO 7 (2,6 DIFLUOROPHENYL) 5H PYRIMIDO[5,4 D][2]BENZAZEPIN 2 YL]AMINO]BENZOIC ACID; AS 703569; AURORA A KINASE; AURORA B KINASE; AURORA C KINASE; AURORA KINASE INHIBITOR; BCR ABL PROTEIN; BOSUTINIB; CYC 116; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DANUSERTIB; DASATINIB; IMATINIB; KW 2449; METHYLPHENIDATE; NILOTINIB; PF 03814735; PROTEIN TYROSINE KINASE INHIBITOR; R 763; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; XL 228;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADENOID CYSTIC CARCINOMA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLADDER CARCINOMA; BREAST CARCINOMA; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTINUOUS INFUSION; CYTOGENETICS; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; FLUID RETENTION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INFUSION RELATED REACTION; LEUKEMIA; LEUKEMIA RELAPSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MITOSIS; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NASOPHARYNX CARCINOMA; NAUSEA; NEOPLASM; NEUTROPENIA; NONHUMAN; OVARY CANCER; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SOLID TUMOR; SOMNOLENCE;

ANIMALS; BENZAMIDES; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES;

EID: 77953216577     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-01222-8_14     Document Type: Review

References (88)

1. Adams RR, Carmena M, Earnshaw WC (2001a) Chromosomal passengers and the (Aurora) ABCs of mitosis. Trends Cell Biol 11:49-54
2. Adams RR, Eckley DM, Vagnarelli P, Wheatley SP, Gerloff DL, Mackay AM, Svingen PA, Kaufmann SH, Earnshaw WC (2001b) Human INCENP colocalizes with the Aurora-B/AIRK2 kinase on chromosomes and is overexpressed in tumour cells. Chromosoma 110:65-74
3. Bernard M, Sanseau P, Henry C, Couturier A, Prigent C (1998) Cloning of STK13, a third human protein kinase related to Drosophila aurora and budding yeast Ipl1 that maps on chromosome 19q13.3-ter. Genomics 53:406-409
4. Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Günther C, Chan CS, Novotny M, Slamon DJ, Plowman GD (1998) A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 17: 3052-3065
5. Bongarzone I, Vigneri P, Mariani L, Collini P, Pilotti S, Pierotti MA (1998) RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clin Cancer Res 4:223-228
6. Boss D, Beijnen JH, Schellens JH (2009) Clinical Experience with Aurora Kinase Inhibitors: A Review. Oncologist 14: 780-793
7. Carmena M, Earnshaw WC (2003) The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 4:842-854
8. Carpinelli P, Ceruti R, Giorgini ML, Cappella P, Gianellini L, Croci V, Degrassi A, Texido G, Rocchetti M, Vianello P, Rusconi L, Storici P, Zugnoni P, Arrigoni C, Marsiglio A, Ballinari D, Pesenti E, Fancelli D, Moll J (2007) Danusertib , a potent inhibitor of aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 6:3158-3168
9. Carpinelli P, Moll J (2007) Aurora kinases and their inhibitors: more than one target and one drug. Adv Exp Med Biol 610:54-73
10. Castro A, Arlot-Bonnemains Y, Vigneron S, Labbe JC, Prigent C, Lorca T (2002a) APC/Fizzy-related targets Aurora A kinase for proteolysis. EMBO Rep 3:457-462
11. Castro A, Vigneron S, Bernis C, Labbe JC, Prigent C, Lorca T (2002b) The D-Box-activating domain (DAD) is a new proteolysis signal that stimulates the silent D-Box sequence of Aurora A. EMBO Rep 3:1209-1214
12. Cheetam GMT, Knegtel RMA, Coll JT, Renwick SB, Swenson L, Weber P, Lippke JA, Austen DA (2000) Crystal structure of Aurora-2, an oncogenic serine/threonine kinase. J Biol Chem 277: 42419-42422
13. Chieffi P, Cozzolino L, Kisslinger A, Libertini S, Staibano S, Mansueto G, De Rosa G, Vilacci A, Vitale M, Linardopoulos S, Portella G, Tramontano D (2006) Aurora B expression directly correlates with prostate cancer malignancy and influences prostate cell proliferation. Prostate 66:326-333
14. Cohen RB, Jones SF, Aggarwal C, Von Mehren M, Cheng J, Spigel DR, Greco FA, Mariani M, Rocchetti M, Ceruti R, Comis S, Laffranchi B, Moll J, Burris HA (2009) A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-hour Infusion With and Without G-CSF in a 14-day Cycle in Patients with Advanced Solid Tumors. Clin Cancer Res.; in press
15. Cortes J, Roboz GJ, Kantarjian H, Feldman E, Karp J, Pollack A, Sandy K, Rao N, Akinaga S, Levis M (2007) A phase I dose escalation study of KW-2449, an oral multikinase inhibitor against FLT3, ABL, FGFR1, and Aurora in patients with relapsed/ refractory AML, treatment resistant/intolerant CML, ALL, MDS. Blood 110:abstr. 909
16. De Jonge M (2006) A phase I dose-escalation study of Danusertib administered as a 6-hour infusion on days 1, 8, and 15 every 4 weeks in patients with advanced/metastatic solid tumors. VIII Congress of the Italian Association of Medical Oncology (IAOM), Milan, Italy
17. Dewar H, Tanaka K, Nasmyth K, Tanaka TU (2004) Tension between two kinetochores siffices for their biorientation on the mitotic spindle. Nature 428:93-97
18. DiCioccio RA, Song H, Waterfall C, Kimura MT, Nagase H, McGuire V, Hogdall E, Shah MN, Luben RN, Easton DF, Jacobs IJ, Ponder BAJ, Whittemore AS, Gayther SA, Pharoah PDP, Kruger-Kjaer S (2004) STK15 polymorphisms and association with risk of invasive ovarian cancer. Cancer Epidemiol Biomark Prev 13: 1589-1594
19. Dionne CA, Camoratto AM, Jani JP, Emerson E, Neff N, Vaught JL, Murakata C, Djakiew D, Lamb J, Bova S, George D, Isaacs JT (1998) Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587). Clin Cancer Res 4:1887-1898
20. Ditchfield C, Johnson VL, Tighe A, Ellston R, Haworth C, Johnson T, Mortlock A, Keen N, Taylor SS (2003) Aurora B couples chromosome alingment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 161:267-280
21. Egan KM, Newcomb PA, Ambrosone CB, Trentham-Dietz A, Titus-Ernstoff L, Hampton JM, Kimura MT, Nagase H (2004) STK15 polymorphism and breast cancer risk in a populationbased study. Carcinogenesis 25:2149-2153
22. Ewart-Toland A, Briassouli P, De Koning JP, Mao JH, Yuan J, Chan F, MacCarthy-Morrogh L, Ponder BA, Nagase H, Burn J, Ball S, Almeida M, Linardopoulos S, Balmain A (2003) Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet 34:403-412
23. Fu J, Bian M, Jiang Q, Zhang C (2007) Roles of aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 5:1-10
24. Galvin KM, Huck J, Burenkova O, Burke K, Bowman D, Shinde V, Stringer B, Zhang M, Manfredi M, Meetze K (2006) Preclinical pharmacodynamic studies of Aurora-A inhibition by MLN8054. J Clin Oncol 24(20 Suppl): 13059
25. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN, Gandara DR (2008) Aurora Kinases as Anticancer Drug Targets. Clin Cancer Res 14: 1639-1648
26. Giet R, Glover DM (2001) Drosophila aurora B kinase is required for histone H3 phosphorylation and condensin recruitment during chromosome condensation and to organize the central spindle during cytokinesis. J Cell Biol 152: 669-682
27. Giet R, Prigent C (1999) Aurora/Ipl 1p-related kinases, a new oncogenic family of mitotic serine-threonine kinases. J Cell Sci 112:3591-3601
28. Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ (2007) MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109: 500-502
29. Glover DM, Leibowitz MH, McLean DA, Parry H (1995) Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell 81:95-105
30. Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E, Benten D, Bokemeyer C, Fiedler W, Moll J, Brümmendorf TH (2008) Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor Danusertib is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 111:4355-4364
31. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O'Meara S, Vastrik I, Schmidt EE, Avis T, Barthorpe S, Bhamra G, Buck G, Choudhury B, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Menzies A, Mironenko T, Perry J, Raine K, Richardson D, Shepherd R, Small A, Tofts C, Varian J, Webb T, West S, Widaa S, Yates A, Cahill DP, Louis DN, Goldstraw P, Nicholson AG, Brasseur F, Looijenga L, Weber BL, Chiew YE, DeFazio A, Greaves MF, Green AR, Campbell P, Birney E, Easton DF, Chenevix-Trench G, Tan MH, Khoo SK, Teh BT, Yuen ST, Leung SY, Wooster R, Futreal PA, Stratton MR (2007) Patterns of somatic mutation in human cancer genomes. Nature 446:153-158
32. Gritsko TM, Coppola D, Paciga JE, Yang L, Sun M, Shelley SA, Fiorica JV, Nicosia SV, Cheng JQ (2003) activation and over-expression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res 9:1420-1426
33. Gurley LR, D'Anna JA, Barham SS, Deaven LL, Tobey RA (1978) Histone phosphorylation and chromatin structure during mitosis in Chinese hamster cells. Eur J Biochem 84:1-15
34. Hampton T (2007) New blood cancer therapies under study. JAMA 297:457-458
35. Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD (2002) Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 62: 2890-2896
36. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayam T, Graham JA, Demur C, Hercend T, Diu-Hercend A, Su M, Golec JM, Miller KM (2004) VX-680, a potent and selective small-molecule inhibitor of the aurora kinases, suppresses tumor growth in vivo. Nat Med 10:262-267
37. Hauf S, Cole RW, LaTerra S, Zimmer C, Schnapp G, Walter R, Heckel A, Van Meel J, Rieder CL, Peters JM (2003) The small molecule Hesperadin reveals a role for aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 161:281-294
38. Hu HM, Chuang CK, Lee MJ, Tseng TC, Tang TK (2000) Genomic organization, expression, and chromosome localization of a third aurora-related kinase gene, Aie1. DNA Cell Biol 19: 679-688
39. Hsu JY, Sun ZW, Li X, Reuben M, Tatchell K, Bishop DK, Grushcow JM, Brame CJ, Caldwell JA, Hunt DF, Lin R, Smith MM, Allis CD (2000) Mitotic phosphorylation of histone H3 is governed by Ipl1/aurora kinase and Glc7/PP1 phosphatase in budding yeast and nematodes. Cell 102:279-291
40. Jeng YM, Peng SY, Lin CY, Hsu HC (2004) Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 10: 2065-2071
41. Jiang N, Wang X, Yang Y, Dai W (2006) Advances in mitotic inhibitors for cancer treatment. Mini Rev Med Chem 6:885-895
42. Jones SF, Cohen RB, Dees EC, Lee Y, Papas JA, Cooper MR, Galvin KM, Burris HA (2007) Phase I clinical trial of MLN8054, a selective inhibitor of aurora A kinase. Proc Am Soc Clin Oncol Annu Meet 25:3577
43. Ju H, Cho H, Kim YS, Kim WH, Ihm C, Noh SM, Kim JB, Hahn DS, Choi BY, Kang C (2006) Functional polymorphism 57 Val>Ile of aurora kinase A associated with increased risk of gastric cancer progression. Cancer Lett 242: 273-279
44. Katayama H, Ota T, Jisaki F, Ueda Y, Tanaka T, Odashima S, Suzuki F, Terada Y, Tatsuka M (1999) Mitotic kinase expression and colorectal cancer progression. J Natl Cancer Inst 91: 1160-1162
45. Keen N, Taylor S (2009) Mitotic drivers-inhibitors of the Aurora B Kinase. Cancer Metastasis Rev 28: 185-195
46. Kimura M, Matsuda Y, Yoshioka T, Okano Y (1999) Cell cycle-dependent expression and centrosome localization of a third human aurora/Ipl 1-related protein kinase, AIK3. J Biol Chem 274:7334-7340
47. Kimura M, Matsuda Y, Yoshioka T, Sumi N, Okano Y (1998) Identification and characterization of STK12/Aik2: a human gene related to aurora of Drosophila and yeast IPL1. Cytogenet Cell Genet 82:147-152
48. Kimura MT, Mori T, Conroy J, Nowak NJ, Satomi S, Tamai K, Nagase H (2005) Two functional coding single nucleotide polymorphisms in STK15 (aurora-A) coordinately increase esophageal cancer risk. Cancer Res 65:3548-3554
49. Lengauer C, Kinzler KW, Vogelstein B (1998) Genetic instabilities in human cancers. Nature 396: 643-649
50. Li D, Zhu J, Firozi PF, Abbruzzese JL, Evans DB, Cleary K, Friess H, Sen S (2003) Over-expression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res 9: 991-997
51. Littlepage LE, Wu H, Andresson T, Deanehan JK, Amundadottir LT, Ruderman JV (2002) Identification of phosphorylated residues that affect the activity of the mitotic kinase Aurora-A. Proc Natl Acad Sci USA 99:15440-15445
52. Lugo TG, Pendergast AM, Muller AJ, Witte ON (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247:1079-1082
53. Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, Galvin KM, Hoar KM, Huck JJ, Leroy PJ, Ray ET, Sells TB, Stringer B, Stroud SG, Vos TJ, Weatherhead GS, Wysong DR, Zhang M, Bolen JB, Claiborne CF (2007) Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora-A kinase. Proc Natl Acad Sci USA 104:4106-4111
54. Marumoto T, Hirota T, Morisaki T, Kunitoku N, Zhang D, Ichikawa Y, Sasayama T, Kuninaka S, Mimori T, Tamaki N, Kimura M, Okano Y, Saya H (2002) G2 checkpoint in mammalian cells. Genes Cells 7:1173-1182
55. Meraldi P, Honda R, Nigg EA (2002) Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53/cells. EMBO J 21:483-492
56. Miao X, Sun T, Wang Y, Zhang X, Tan W, Lin D (2004) Functional STK15 Phe31Ile polymorphism is associated with the occurrence and advanced disease status of esophageal squamous cell carcinoma. Cancer Res 64:2680-2683
57. Modugno M, Casale E, Soncini C, Rosettani P, Colombo R, Lupi R, Rusconi L, Fancelli D, Carpinelli P, Cameron AD, Isacchi A, Moll J (2007) Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor Danusertib. Cancer Res 67:7987-7990
58. Monier K, Mouradian S, Sullivan KF (2007) DNA methylation promotes aurora-B -driven phosphorylation of histone H3 in chromosomal subdomains. J Cell Sci 120:101-114
59. Neben K, Korshunov A, Benner A, Wrobel G, Hahn M, Kokocinski F, Golanov A, Joos S, Lichter P (2004) Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res 64:3103-3111
60. Nigg EA (2001) Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2:21-32
61. Ohi R, Sapra T, Howard J, Mitchison TJ (2004) Differentiation of cytoplasmatic and meiotic spindle assembly MCAK functions by Aurora B-dependent phosphorylation. Mol Biol Cell 15: 2895-2906
62. Ota T, Suto S, Katayama H, Han ZB, Suzuki F, Maeda M, Tanino M, Terada Y, Tatsuka M (2002) Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res 62:5168-5177
63. Paquette R, Shah NP, Sawyers CL, Martinelli G, John N, Chalukya M, Rocchetti M, Fiocchi C, Comis S, Capolongo L, Laffranchi B (2007) Danusertib , an Aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL. Blood 110:abstr. 1030
64. Propp S, Lizzi FA (1970) Philadelphia chromosome in acute lymhocytic leukemia. Blood 36: 353-360
65. Ravandi F, Foran J, Verstovsek S, Cortes J, Wierda W, Boone P, Borthakur G, Sweeney T, Kantarjian H (2007) A phase I trial of AT9283, a multitargeted kinase inhibitor, in patients with refractory hematological malignancies. Blood 110:abstr. 904
66. Rubin EH, Shapiro GI, Stein MN, Watson P, Bergstrom D, Xiao A, Clark JB, Freedman SJ, Eder JP (2006) A phase I clinical and pharmacokinetic (PK) trial of the aurora kinase (AK) inhibitor MK-0457 in cancer patients. J Clin Oncol 24:abstr. 3009
67. Sasai K, Katayama H, Stenoien DL, Fujii S, Honda R, Kimura M, Okano Y, Tatsuka M, Suzuki F, Nigg EA, Earnshaw WC, Brinkley WR, Sen S (2004) Aurora C kinase is a novel chromosomal passenger protein that can complement Aurora B kinase function in mitotic cells. Cell Motil Cytoskeleton 59:249-263
68. Schellens JH, Boss D, Witteveen PO, Zandvliet A, Beijnen JH, Voogel-Fuchs M, Morris C, Wilson D, Voest EE (2006) Phase I and pharmacological study of the novel aurora kinase inhibitor AZD1152. J Clin Oncol 24(20 Suppl):3008
69. Schmidt M, Bastians H (2007) Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist Updat 10:162-181
70. Sen S, Zhou H, White RA (1997) A putative serine/ threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene 14: 2195-2200
71. Sen S, Zhou H, Zhang RD, Yoon DS, Vakar-Lopez F, Ito S, Jiang F, Johnston D, Grossman HB, Ruifrok AC, Katz RL, Brinkley W, Czerniak B (2002) Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 94:1320-1329
72. Shah NP, Kasap C, Paquette R, Cortes J, Pinilla J, Talpaz M, Bui LA, Clary DO (2007) Targeting drug-resistant CML and Ph ALL with the spectrum selective protein kinase inhibitor XL228. Blood 110:abstr. 474
73. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farell C, Meeh P, Markowitz SD, Willis J, dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314:268-274
74. Smith SL, Bowers NL, Betticher DC, Gautschi O, Ratschiller D, Hoban PR, Booton R, Santibanez-Koref MF, Heighway J (2005) Overexpression of aurora B kinase (AURKB) in primary nonsmall cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability. Br J Cancer 93: 719-729
75. Sorrentino R, Libertini S, Pallante PL, Troncone G, Palombini L, Bavetsias V, Spalletti-Cernia D, Laccetti P, Linardopoulos S, Chieffi P, Fusco A, Portell G (2004) Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab 90:928-935
76. Steeghs N, Eskens F, Gelderblom H, Verweij J, Nortier J, Ouwerkerk J, Van Noort C, Mariani M, Spinelli R, Carpinelli P, Laffranchi B, De Jonge M (2009) A Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor PHA-739358 in Patients with Advanced or Metastatic Solid Tumors. J Clin Oncol; in press
77. Takahashi T, Futamura M, Yoshimi N, Sano J, Katada M, Takagi Y, Kimura M, Yoshioka T, Okano Y, Saji S (2000) Centrosomal kinases, HsAIRK1 and HsAIRK3, are overexpressed in primary colorectal cancers. Jpn J Cancer Res 91: 1007-1014
78. Tanaka T, Kimura M, Matsunaga K, Fukada D, Mori H, Okano Y (1999) Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res 59:2041-2044
79. Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T, Borg A, Isola JJ (2000) Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res 6: 1833-1839
80. Tatsuka M, Katayama H, Ota T, Tanaka T, Odashima S, Suzuki F, Terada Y (1998) Multinuclearity and increased ploidy caused by overexpression of the aurora- and lpl1-like midbody-associated protein kinase in human cancer cells. Cancer Res 58:4811-4816
81. Tsai MY, Wiese C, Cao K, Martin O, Donovan P, Ruderman J, Prigent C, Zheng Y (2003) A Ran signalling pathway mediated by the mitotic kinase Aurora A in spindle assembly. Nat Cell Biol 5:242-248
82. Vader G, Medema RH, Lens SM (2006) The chromosomal passenger complex: guiding aurora-B through mitosis. J Cell Biol 173:833-837
83. Wang X, Zhou YX, Qiao W, Tominaga Y, Ouchi M, Ouchi T, Deng CX (2006) Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene 25: 7148-7158
84. Warner SL, Bearss DJ, Han H, Von Hoff DD (2003) Targeting Aurora-2 kinase in cancer. Mol Cancer Ther 2:589-595
85. Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, Biggs WH III, Treiber DK, Patel HK, Zarrinkar PP, Lockhart DJ, Sawyers CL, Kuriyan J (2006) Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 66:1007-1014
86. Zeitlin SG, Shelby RD, Sullivan KF (2001) CENP-A is phosphorylated by Aurora B kinase and plays an unexpected role in completion of cytokinesis. J Cell Biol 155:1147-1157
87. Zhang W (2006) Inhibition of the drug-resistant T315I mutant of BCR-ABL. Eur J Cancer Suppl 4:54
88. Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkley BR, Sen S (1998) Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 20:189-193